Skip to content

Proteins From Duckweed Trial

Proteins From Duckweed Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03823222
Acronym
ProDuckT
Enrollment
12
Registered
2019-01-30
Start date
2019-02-28
Completion date
2019-03-28
Last updated
2019-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degree of Digestilbility

Keywords

Duckweed protein, protein, degree of digestibility, whey protein

Brief summary

This study aims to study the digestibility of isolated duckweed protein. The digestibility of the isolated duckweed protein will be compared to an isolated benchmark protein whey. Objective: The primary objective is to investigate the digestibility of isolated duckweed protein and the isolated benchmark protein whey. Study design: The study is a cross-over, double blind, controlled trial in which study participants will visit the research facility on two occasions under fasting conditions. Subjects will receive two protein sources in randomized order with a washout period of one week. Blood will be collected via a catheter before and up-to 3 hours after protein consumption. Study population: We aim to include 12 healthy volunteers aged 18-50 years. Intervention: Study participants will receive 20 grams of isolated duckweed protein and the isolated benchmark protein whey. Main study parameters/endpoints: The main study parameter is blood amino acids measured before and after consumption of 20 g protein.

Interventions

DIETARY_SUPPLEMENTDuckweed protein

20 grams isolated protein

DIETARY_SUPPLEMENTWhey protein

20 grams isolated protein

Sponsors

Wageningen University and Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Body mass index (BMI) between 18 and 25 kg/m2 * Having veins suitable for blood sampling via a catheter (judged by study nurse/ medical doctor)

Exclusion criteria

* Any metabolic, gastrointestinal, inflammatory or chronic disease (such as diabetes, anaemia, hepatitis, cardiovascular disease) * History of gastro-intestinal surgery or having (serious) gastro-intestinal complaints * History of liver dysfunction (cirrhosis, hepatitis) or liver surgery * Kidney dysfunction (self-reported) * Use of medication that may influence the study results, such as gastric acid inhibitors, laxatives, stomach protectors and drugs that can affect intestinal motility * Anaemia (Hb values \<7.5 for women and \<8.5 for men) * Reported slimming, medically prescribed, vegan/vegetarian or other extreme diets or the use of protein supplements * Not willing to give up blood donation during the study * Current smokers * Alcohol intake ≥4 glasses of alcoholic beverages per day * Pregnant, lactating or wishing to become pregnant in the period of the study (self-reported) * Abuse of illicit drugs * Food allergies for products that we use in the study * Participation in another clinical trial at the same time * Being an employee of the department Consumer Science & Health group of Wageningen Food & Biobased Research

Design outcomes

Primary

MeasureTime frameDescription
Change in blood free amino acids (e.g. Degree of digestibility)20 gram protein will be consumed and blood samples will be taken before and up to 3 hours after protein consumptionpostprandial test, determine free amino acids in blood samples collected before and after a postprandial challenge test

Secondary

MeasureTime frameDescription
change in plasma insulin20 gram protein will be consumed and blood samples will be taken before and up to 3 hours after protein consumptionbefore and after a postprandial challenge test
change in plasma glucose20 gram protein will be consumed and blood samples will be taken before and up to 3 hours after protein consumptionbefore and after a postprandial challenge test

Other

MeasureTime frameDescription
change in visual analogue scale (VAS) scores on intestinal complainsdaily from day1 until day3 after the interventionOn a scale ranging from worst-best outcome (higher scores are better)

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026